Business Context and Reporting Period
Company: MacroGenics, Inc.
Filing Type: Form 8-K (Current Report)
Date: June 19, 2020
Event: Amendment to an existing Sales Agreement with Cowen and Company, LLC to increase the capacity for selling common stock.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. It focuses exclusively on capital raising activities.
- Amended Offering Capacity: Increased from $50.0 million to $175.0 million.
- Shares Sold to Date: 2,269,745 shares.
- Gross Proceeds to Date: $50.0 million (before discounts and fees).
- Commission Rate: Up to 3.0% of the gross sales price.
Material Changes
The primary material change is the expansion of the "at-the-market" (ATM) equity offering program. The aggregate offering price limit under the Sales Agreement with Cowen was raised by $125.0 million, allowing the company to raise up to $175.0 million in total under this facility.
Outlook, Risks, and Management Commentary
Management Commentary: The company retains the right to suspend offers or terminate the Sales Agreement at any time and has no obligation to sell any shares. Sales are conducted based on the company's instructions and market conditions.
Risks and Contingencies:
- Sales are subject to market conditions and the company's discretion.
- The offering is subject to the terms of the Sales Agreement and the effective shelf registration statement (Form S-3).
- Offers are not valid in jurisdictions where such offers would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to an additional $125.0 million in shares.
- Review the full text of Amendment No. 1 (Exhibit 1.2) for specific terms and conditions.
- Monitor future 8-K filings for actual sales volumes and proceeds generated under the expanded facility.
- Confirm the company's cash position and burn rate to understand the necessity of this capital raise.